Fox Run Management L.L.C. Makes New $783,000 Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fox Run Management L.L.C. purchased a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 23,839 shares of the biopharmaceutical company's stock, valued at approximately $783,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after buying an additional 216,484 shares in the last quarter. Vestal Point Capital LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter valued at $33,767,000. BNP Paribas Financial Markets raised its position in Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares during the last quarter. FMR LLC boosted its stake in Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock worth $2,017,000 after purchasing an additional 33,546 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals during the third quarter worth $892,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company's stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.93% of the company's stock.

Remove Ads

Analysts Set New Price Targets

AGIO has been the subject of a number of research analyst reports. Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright began coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Finally, StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded down $0.56 on Friday, hitting $30.28. 328,199 shares of the company's stock traded hands, compared to its average volume of 701,317. Agios Pharmaceuticals, Inc. has a one year low of $27.14 and a one year high of $62.58. The stock has a market capitalization of $1.73 billion, a PE ratio of 2.67 and a beta of 0.90. The firm's 50-day moving average price is $33.17 and its two-hundred day moving average price is $40.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.